A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)

Trial Profile

A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-394
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 May 2017 Status changed from not yet recruiting to recruiting.
    • 31 Mar 2017 Planned End Date changed from 1 Sep 2019 to 23 Dec 2019.
    • 31 Mar 2017 Planned primary completion date changed from 1 Sep 2019 to 23 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top